GE HealthCare (GEHC)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$85.81+6.38%
Close 2026-11-04 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
Research Workspace
Put GEHC beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Health Care Equipment: fringe margins under pressure (4q confirmed)
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Profit margin near 16% in 2026: Operating margin: 14.6%.
View ThesisRevenue is growing steadily — about 7% over the past year.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look reasonable — what the market is pricing in sits in line with or below what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskGE HealthCare's Pharmaceutical Diagnostics expansion has to keep compounding to justify the price. Revenue grew 7.2% year over year in the latest quarter. The company beat earnings estimates by 10.7% in Q3 2026. It trades at 18x earnings versus a 33x peer median. The price reflects less growth than we forecast. Operating margin sits at 14.6% against a 15.4% target. A voluntary software recall adds execution risk. Peer multiples imply a price about 10% below where it trades. The thesis is on watch. This read is provisional.
Trailing returns as of 2026-11-04. GEHC is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 22 analysts currently covering GEHC (as of Nov 2026).
Based on 6 Wall Street analysts offering 12-month price targets for GEHC in the last 4 months.
Continue this research
Compare GEHC with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| GEHC Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-11-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Health Care Equipment — fair value, gap to price, and forward P/E.
Compare the value case
Put GEHC next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Expand adjusted EBIT margin to 15.4%-15.7% in 2026
Reported Q3 margin gains directly support the 2026 margin objective, though the headline alone gives limited detail.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $85.81
The last 12 months of price, then the range of analyst 12-month targets from today’s $85.81.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Advances: Drive organic revenue growth of 3-4% in 2026
Strong Q3 results and raised outlook support revenue growth, though details are needed to assess margin and cash flow.
Advances: Advance innovation and commercial expansion in Pharmaceutical Diagnostics
Supports innovation and commercial expansion in Pharmaceutical Diagnostics.
Advances: Advance innovation and commercial expansion in Pharmaceutical Diagnostics
Acquisition enhances innovation and commercial expansion in diagnostics.
Acquisition supports growth and innovation in diagnostics.
Potential acquisition aligns with growth and innovation objectives.
Advances: Advance innovation and commercial expansion in Pharmaceutical Diagnostics
CE mark enhances innovation in Pharmaceutical Diagnostics.
Advances: Increase revenue growth
AI oncology push aligns with revenue growth objective.